期刊
MOVEMENT DISORDERS
卷 30, 期 1, 页码 45-53出版社
WILEY
DOI: 10.1002/mds.26103
关键词
Parkinson's Disease; levodopa; dyskinesia; presynaptic; dopamine; serotonin
资金
- NIDA NIH HHS [P01 DA010154, R01 DA007418] Funding Source: Medline
- NINDS NIH HHS [R01 NS075222, R01NS075222, P50 NS038370] Funding Source: Medline
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038370, R01NS075222] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010154, R01DA007418] Funding Source: NIH RePORTER
Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients. (c) 2014 International Parkinson and Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据